Our take
Lifeward sells the ReWalk, the first exoskeleton cleared by the FDA for personal use, along with AlterG anti-gravity treadmills for clinics. Its pricing is unusually visible for medical robotics because Medicare set a lump-sum fee of $91,032 for personal exoskeletons in 2024, and Aetna, Humana, and UnitedHealthcare added Medicare Advantage coverage in 2025.5,2,6
The business is small and in flux. Revenue fell 14% to $22.0 million in 2025, the company lost $19.9 million, and it agreed to a deal that could give Oramed up to 49.99% of its shares. Second-quarter 2026 revenue rose 16% to $6.6 million, and Josh Hexter took over as interim CEO in September 2026.2,3,4
Scores by criterion
Each criterion is defined on our methodology page.
Who uses Lifeward and what it's for
The ReWalk Personal Exoskeleton serves people with spinal cord injury who want to stand and walk at home and in the community, and is often bought through Medicare, the Veterans Health Administration, or private insurers. AlterG systems serve rehabilitation clinics, sports teams, and hospitals.5,2
Lifeward sells directly in the United States and through a mix of direct sales and distributors in Germany, Canada, and Australia.5
ReWalk, AlterG, and ReStore
ReWalk uses tilt sensors, an onboard computer, and motorized legs to let people with paraplegia stand and walk. The FDA cleared stair and curb use in 2023, and ReWalk 7 is the newest model.5,1
Lifeward bought AlterG in August 2023 for about $19 million. AlterG treadmills use NASA-derived differential air pressure to reduce body weight during rehabilitation and are used in more than 4,000 facilities in more than 40 countries. Lifeward also sells the ReStore soft exo-suit for stroke and distributes MYOLYN FES cycles.5
Finances and the Oramed deal
2025 revenue was $22.0 million, down from $25.7 million, with ReWalk sales of $8.5 million. Net loss narrowed to $19.9 million, and the company ended the year with $2.2 million in unrestricted cash.2
Shareholders approved a deal with Oramed Pharmaceuticals under which Lifeward acquires Oramed's oral protein delivery technology and Oramed can own up to 49.99% of Lifeward. Lifeward had $9.4 million in cash at June 30, 2026.2,3
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where Lifeward wins or loses |
|---|---|---|---|---|
| Lifeward | ReWalk personal exoskeleton and AlterG anti-gravity systems2 | Medicare fee of $91,032 for a personal exoskeleton5 | Individual users through Medicare and insurers; AlterG in more than 4,000 facilities5 | Personal use with an established Medicare fee; small, loss-making company |
| Ekso Bionics | EksoNR exoskeleton for gait training after stroke and brain injury10 | Not published10 | Inpatient rehabilitation facilities; first exoskeleton FDA-cleared for stroke10 | Lifeward wins on personal use at home with a Medicare fee. Ekso wins in inpatient rehabilitation for stroke. |
| Wandercraft | Eve self-balancing personal exoskeleton and Atalante X for clinics12,11 | Not published12 | More than 150 clinical centers; acquired Ekso Bionics in 202612,13 | Lifeward wins on a longer record and a Medicare fee. Wandercraft wins on hands-free, self-balancing walking. |
| Myomo | MyoPro powered arm and hand brace22 | Medicare fee schedule rates of $33,481 and $65,87215 | Patients reached through clinician referrals and orthotics and prosthetics channels16,23 | Lifeward wins on walking for people with spinal cord injury. Myomo wins on arm and hand function. |
| Saebo (SaeboFlex) | Non-powered dynamic hand splint with springs that reopen the hand18 | Not published; custom-fit by a trained professional18 | Outpatient clinics and rehabilitation facilities18 | Lifeward wins on powered walking. Saebo wins on low-cost hand rehabilitation. |
| Cyberdyne | Medical HAL wearable robot driven by the wearer's bioelectric signals19 | Not published; mainly rentals and treatment services20 | Approvals or certifications in more than 20 countries24 | Lifeward wins on a personal device with a Medicare fee. Cyberdyne wins on clinic treatment across more indications. |
Limits
Cash is tight. The company has relied on financing deals and the Oramed transaction to fund operations.2,3
Leadership changed in 2026. Mark Grant left as CEO and Josh Hexter is interim CEO.4 Rami Aviram, named CFO in August, withdrew before starting, and Ronen Tsimerman has been CFO since November 1, 2026.8,9
The new oral drug delivery business is unrelated to robotics and may pull attention from the core rehabilitation products.2
Rivals are consolidating. Wandercraft acquired Ekso Bionics on October 1, 2026, putting two of Lifeward's exoskeleton competitors under one owner. See our Wandercraft review.7
What customers say
Where it helps
Coverage is the main help for patients. Medicare has a fee schedule for personal exoskeletons, and Medicare Advantage coverage from Aetna, Humana, and UnitedHealthcare reaches about 16 million covered lives, according to Lifeward.5,2
Where it falls short
We found no independent customer reviews. The concerns in public filings are financial: a revenue decline in 2025, continued losses, and dependence on outside financing.2
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: Lifeward SEC filings, earnings releases, and website.
Leadership

Josh Hexter
Interim chief executive officerHexter became interim CEO on September 1, 2026. He was previously chief operating and business officer of Oramed Pharmaceuticals and chief business officer of BrainsWay.4

Sources
- Lifeward, Homepage, accessed November 2, 2026
- Lifeward, Lifeward reports fourth quarter and full year 2025 financial results, March 18, 2026, accessed November 2, 2026
- Lifeward, Lifeward reports strong second quarter 2026 financial results, August 14, 2026, accessed November 2, 2026
- Lifeward, Lifeward appoints Josh Hexter interim chief executive officer, August 31, 2026, accessed November 2, 2026
- Lifeward, Form 10-Q for the quarter ended September 30, 2024, accessed November 2, 2026
- Wikipedia, ReWalk, accessed November 2, 2026
- Wandercraft, Wandercraft acquires Ekso Bionics, October 1, 2026, accessed November 2, 2026
- Lifeward, Form 8-K, October 8, 2026, accessed November 2, 2026
- Lifeward, Form 8-K, October 27, 2026, accessed November 2, 2026
- Ekso Bionics, EksoNR, accessed November 1, 2026
- Wandercraft, Atalante X, accessed November 1, 2026
- Wandercraft, Eve personal exoskeleton, accessed November 1, 2026
- Wandercraft, Wandercraft acquires Ekso Bionics, accessed November 1, 2026
- Myomo, About Myomo, accessed November 1, 2026
- Myomo, CMS posts final Medicare DMEPOS fee schedule rate for the MyoPro, March 1, 2024, accessed October 31, 2026
- Myomo, Second quarter 2026 results, SEC exhibit 99.1, August 5, 2026, accessed October 31, 2026
- Saebo, Home page, accessed November 1, 2026
- Saebo, SaeboFlex, accessed November 1, 2026
- Cyberdyne, Medical HAL lower limb type, accessed November 2, 2026
- Cyberdyne, Financial results briefing for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
- Cyberdyne, Consolidated financial results for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
- Myomo, Homepage, accessed October 31, 2026
- Myomo, Fourth quarter and full year 2025 results, accessed October 31, 2026
- Cyberdyne, About Cyberdyne, accessed November 3, 2026

